Global Newsroom

^{_{CSL Behring Patient Zahra Khan, living with hereditary angioedema}}

Featured News

CSL

Jul 27, 2026

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress

Read more about CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

Latest News

CSL Vifor

Aug 6, 2026

A further update on TAVNEOS® (avacopan) in the European Union

Dear ANCA‑associated vasculitis community, Further to our last update regarding TAVNEOS® (avacopan), we wanted to inform you that the European Commission (EC) has adopted a decision revoking...

Read more about A further update on TAVNEOS® (avacopan) in the European Union

CSL Vifor

Aug 6, 2026

European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries

ST. GALLEN, SWITZERLAND – 6 August, 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Commission (EC) has adopted the decision revoking the...

Read more about European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries

CSL

Jul 27, 2026

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress

Read more about CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

Jul 24, 2026

Our Continued Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Supply and Patient Access

Read more about Our Continued Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Supply and Patient Access

Jun 26, 2026

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor...

Read more about CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Vita: Original Stories

'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.

Loading...

Media Resources

Takes you to CSL History
CSL History

Media Contacts

Australia
Brett Foley
Phone: +61 461 464 708
Email: media@csl.com.au

North America
Email: MediaNorthAmerica@cslbehring.com

Europe
Email: MediaEurope@csl.com.au

Asia Pacific
Email: MediaAsiaPacific@cslbehring.com

CSL Plasma requests should be sent to MediaNorthAmerica@cslbehring.com

North America
Melanie Kerin
Email: melanie.kerin@seqirus.com

Asia Pacific
Hamish Walsh
Phone: +61 422 424 338
Email: Hamish.Walsh@seqirus.com

Global Commercial Development; UK, EMA, Argentina
Emmanuella Dekonor
Phone: +44 7920500496
Email: Emmanuella.Dekonor@seqirus.com

Switzerland
MediaEurope@csl.com.au

Global Newsroom

Follow Us Online